Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of ARGX-119 in healthy adults
NL-OMON53520Phase 1Completed
- Sponsor
- argenx
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adimanebart in congenital myasthenic syndrome (CMS) and Neuromuscular junction disease (NMJD) (4 arms), sponsored by argenx. Primary endpoint: Safety and tolerability. Started Feb 2023; status: completed.
02
Drugs
adimanebart
03
Conditions
congenital myasthenic syndrome (CMS)Neuromuscular junction disease (NMJD)
Beyond the preview
Go deeper on NL-OMON53520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53520.